Clinical Trial Update: Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating trastuzumab (NNG-TMAB) for recurrent or metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• NNG-TMAB (Trastuzumab) (Trastuzumab)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Breast Cancer Metastatic, Breast Cancer Recurrent | Phase 3 | Status: COMPLETED